Catalent takes over Zumutor’s lead candidate manufacture

09:30 EST 13 Feb 2020 | BioPharma-Reporter

Under an agreement with Zumutor, Catalent Biologics initiates clinical manufacture of the latterâs lead candidate targeting solid tumors, ahead of FDA filing.

Original Article: Catalent takes over Zumutor’s lead candidate manufacture


More From BioPortfolio on "Catalent takes over Zumutor’s lead candidate manufacture"

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...